Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Why's my 8000 buy showing as a sell?
Welcome to aim. Market makers innit
Great strides in commercialisation!
This has to take off at some time surely!
GL.
'The strong results were particularly noteworthy given that the study utilised a generalised 'all-comers' patient population rather than a specific subgroup and examined performance in both the for-cause and surveillance settings. The study was purposefully designed this way to capture the clinical reality across 13 international transplant centres in five countries. As a result, the data reflects the wide clinical applicability of Tutivia? for comprehensive commercial adoption in a real-world setting.'
GL.
(mrkcap £13m) fit into this camp, reflecting positive fundamentals and continued strong execution.
In fact today, Verici announced that a leading US medical publication, The American Journal of Transplantation, had confirmed that its flagship post-surgery test Tutivia "demonstrates strong performance in the assessment of risk of acute rejection following kidney transplant". This is especially important for doctors during the first few weeks post-graft, when patient management can be complex and other biomarkers are contraindicated or less informative.
This milestone represents not only another major endorsement of the quality of
VRCI
’s medical science, but also a further crucial step in the commercialisation of Tutivia. As the company builds industry trust and recognition, it continues to gain local coverage determination (LCD) for Medicare reimbursement - which should in turn increase usage and transplant centre adoption.
Dr. Lorenzo Gallon, Chair of Scientific Advisory Board of Verici Dx commented: "I am delighted that the data from our pivotal validation study for Tutivia has been published in such a high-impact and prestigious journal as The American Journal of Transplantation."
CMO Dr Michael Donovan, DMD, added: "This publication further validates the benefits of the test for kidney transplant patients and their clinicians, and demonstrates the comprehensive design of the study to reflect the full clinical continuum."
COO Patti Connolly, concluded: "We are already seeing growing clinical interest, and as this publication is key in the application for LCD coverage, we anticipate an accelerated adoption of Tutivia within the medical community, marking a significant step forward in enhancing diagnostic accuracy and post-transplant patient care."
Finally regarding financials, Singer Capital Markets are anticipating revenues to jump from $0.3m in FY23 to $8.6m next year while delivering an adjusted EBITDA of $0.1m in 2024 and closing Dec'23 with net cash of $0.1m. They have a BUY rating with a 30p target price.
VRCI
shares jumped 13% on today's announcement.
How under the radar is this still . Good day ,lots more to come atb
Well somebody is slowly racking up the 100k buys. More of a 10k buyer myself!
This is on its way to 30p as it should be.
Agree with accepted commercial tests in the USA I never understood why it was so undervalued!?
GL.
Hopefully a nice strong finish to year end. Update on finalised rates due any day
Got to be one of the most underrated aim shares. Shirley
...agree the shares should easily be 20-30p on the back of the Thermo Fischer deal alone, with only positive news catalysts likely ahead, though the issue may be the company is just too small and illiquid for specialist sector funds to care at this point? So it may be down to us retail and the existing insto fund investors to hoover up the shares before they get acquired sometime in 2024/25. Any material revenue/testing traction in the meantime, will also help the shares re-rate higher.
I added more at 8p on Monday, my average is still under water but not for long!
Revenue is forecast to grow 202.63% per year
What is the source please?
GL.
Thermo fisher will be looking over the numbers as we speak.Buyout sooner rather than later nailed on.
This is getting ready to pop ,great value here totally undervalued .3great products 1st in class and one of the worlds largest pharmas backing to boot just a matter of patience.
That's the kind of thing you type as you press sell for 20k lol
Pharma is coming back into favour.Verici has best in class products and iam sure Thermo will take it out this year ,climb aboard now.
Remember Clarava and Tutivia are now both in the market as real products and with Thermos sales team driving sales 2024 is looking amazing.
Two great rns what a Monday morning . Great work team Verici dx .